unscheduled bleeding unscheduled bleeding
Conditions
Interventions
mefenamic acid,
500 mg,
twice a day for the first five days of each 4 week period for 12 weeks.,placebo same manner as in mefenamic acid group
Experimental Drug,Placebo Comparator No treatment
mefenamic acid,placebo
Sponsors
Khon Kaen university
Khon Kaen university
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: postpartum women who willing to use DMPA for contraception.
Exclusion criteria
Exclusion criteria: - any gynecological disease that could cause abnormal uterine bleeding such as leiomyoma uteri or adenomyosis - coagulopathy - contraindication for mefenamic acid including gastritis, asthma, liver disease or renal disease - contraindication for progestin including o systolic BP more than 160 or diastolic BP more than 100 mmHg o acute deep vein thrombosis o history or current myocardial infarction or stroke o antiphospholipid syndrome o undiagnosed abnormal vaginal bleeding o progesterone receptor positive associated malignancy o severe liver disease or liver tumor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of women who have days of bleeding less than 21 days 3 months percent, chi square | — |
Secondary
| Measure | Time frame |
|---|---|
| number days of bleeding 3 months mean and SD | — |
Countries
Thailand
Contacts
Public Contactjen sothornwit
Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University
Outcome results
None listed